Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.

Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C.

Clin Cancer Res. 2006 Dec 15;12(24):7444-55.


Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.

Davidson DJ, Haskell C, Majest S, Kherzai A, Egan DA, Walter KA, Schneider A, Gubbins EF, Solomon L, Chen Z, Lesniewski R, Henkin J.

Cancer Res. 2005 Jun 1;65(11):4663-72.


Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.

Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, Henkin J.

J Med Chem. 2005 Apr 21;48(8):2838-46.


Synthesis of 4,5-diaryl-1H-pyrazole-3-ol derivatives as potential COX-2 inhibitors.

Patel MV, Bell R, Majest S, Henry R, Kolasa T.

J Org Chem. 2004 Oct 15;69(21):7058-65.


ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.

Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL.

J Pharmacol Exp Ther. 2004 Dec;311(3):904-12. Epub 2004 Jul 26.


Lysyl 4-aminobenzoic acid derivatives as potent small molecule mimetics of plasminogen kringle 5.

Sheppard GS, Kawai M, Craig RA, Davidson DJ, Majest SM, Bell RL, Henkin J.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):965-6.


Supplemental Content

Loading ...
Support Center